07:00 , May 20, 2013 |  BC Week In Review  |  Clinical News

ArteFill: Phase III data

A double-blind, U.S. Phase III trial in about 177 patients with moderate to severe atrophic acne scars showed that ArteFill met the primary endpoint of a greater response rate, defined as a 2-point improvement on...
08:00 , Nov 17, 2008 |  BC Week In Review  |  Company News

Artes dermatology news

Artes hired JMP Securities LLC to explore strategic alternatives while the company continues to seek equity and debt transactions to raise money. Artes markets ArteFill , polymethylmethacrylate (PMMA) microspheres suspended in ultra-purified U.S. bovine collagen...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Clinical News

ArteFill: Post-marketing study completed enrollment

Artes completed enrollment of 1,000 patients in a 5-year, U.S. post-marketing study of ArteFill. The product was approved for the indication by FDA in October 2006. Artes Medical Inc. (NASDAQ:ARTE), San Diego, Calif.   Product:...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Company News

Anika, Artes sales and marketing update

Artes will exclusively distribute Anika's Elevess in the U.S. The hyaluronic acid-based injectable temporary dermal filler with lidocaine is used to treat facial wrinkles. Artes will sell and market the product to dermatologists, plastic surgeons...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Clinical News

ArteColl update

Researchers began a U.S. clinical trial in 10 patients to compare ArteFill injected subdermally throughout the metatarsal area of 1 foot vs. no treatment in the other foot. The study is being sponsored by Artes....
07:00 , Jun 18, 2007 |  BC Week In Review  |  Company News

Artes genitourinary, gastrointestinal news

ARTE created a new subsidiary, Spheris Medical Inc., to develop and commercialize medical applications of ARTE's polymethylmethacrylate (PMMA) microspheres suspended in ultra-purified bovine collagen . The technology is in preclinical testing to bulk the esophageal...